Archives

Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use

Abstract Aims Published literature has raised concerns regarding a causal association between glucagon-like peptide 1 receptor agonist (GLP-1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP-1RA use. Materials and Methods Our evaluation included data from (i) 93 liraglutide or semaglutide phase 2 and […]

Michelle Obama sparks Ozempic weight loss rumors with new photoshoot

Former US first lady, Michelle Obama has sparked Ozempic weight loss rumors after she showed off a seemingly slimmer figure in a new photoshoot. Obama, 61, posed in the new shoot by famed photographer Annie Leibovitz, sharing behind-the-scenes footage on her social media.Before now, the author and podcast host’s fashion choices have been lauded by many, with […]

Novo Nordisk Shares Dropped 12% as Semaglutide Fails Alzheimer’s Trial

Novo Nordisk shares dropped 12% after the company announced that semaglutide, the GLP-1 drug behind Ozempic and Wegovy, failed to show any benefit in slowing cognitive decline in early Alzheimer’s disease. The phase 3 EVOKE and EVOKE-Plus trials found no meaningful difference between semaglutide and placebo on key cognitive and functional measures, prompting Novo Nordisk […]

Michelle Obama’s slimmer look sparks online rumors. Here’s why

Michelle Obama shared photos from a shoot with Annie Leibovitz, sparking baseless speculation about weight-loss medication. While some online users theorized about her appearance, Obama has previously discussed natural changes from menopause and a mindful approach to health. The article also touches on the use and side effects of GLP-1 medications like Ozempic.

$NVO Faces Market Pressure Follow by Alzheime Clinical Trial

$NVO Faces Market Pressure Follow by Alzheime Clinical Trial Novo Nordisk A/S Sponsored ADR Class B BATS:NVO KalaGhazi Shares of Novo Nordisk (NYSE: NVO) found themselves among the session’s most significant decliners on Monday, pressured by discouraging news from the pharmaceutical giant’s pipeline. The company announced that its highly anticipated clinical trial, which investigated the […]

Weight-loss drug no silver bullet for Alzheimer’s as big trial fails

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer’s disease (AD), as two-year clinical trials end in disappointment for patients, medical scientists and drugmaker Novo Nordisk. Continue Reading Category: Alzheimer’s & Dementia, Brain Health, Body and Mind Tags: Novo Nordisk, Alzheimer’s disease, Semaglutide, Ozempic, clinical trials, Inflammation, Brain, GLP-1 […]

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials – The New York Times

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials  The New York Times Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says  CNN Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials  The Guardian Obesity jab drug fails to slow Alzheimer’s  BBC There’s still hope GLP-1 drugs could slow the second-biggest […]

What are The Economist’s predictions for 2026?

PHOTO ART: MERCA2.0 The Economist published its traditional end-of-year special edition, The World Ahead 2026, an in-depth analysis projecting the key themes and trends that will reshape the global landscape over the next twelve months. Now in its 40th edition, the report has become one of the most influential publications for anticipating political, economic, and […]